Abstracts tagged "clinical trials and osteoarthritis"

Abstract Number: L03 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety from a Phase 2b Trial of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor for the Treatment of Osteoarthritis of the Knee
Yusuf Yazici¹, Timothy E. McAlindon², Allan Gibofsky³, Nancy Lane⁴, Christian Lattermann⁵, Nebojsa Skrepnik⁶, Christopher Swearingen¹, Anita DiFrancesco¹, Jeymi Tambiah¹ and Marc Hochberg⁷, ¹Samumed, LLC, San Diego, CA, ²Division of Rheumatology, Tufts Medical Center, Boston, MA, ³Rheumatology, Weill Cornell Medicine, and Hospital for Special Surgery, New York, NY, ⁴Center for Musculoskeletal Health, University of California, Davis School of Medicine, Sacramento, CA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Tucson Orthopaedic Institute, Tucson, AZ, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: A previous Phase 2a study of SM04690, a small molecule, intra-articular (IA), Wnt pathway inhibitor, demonstrated positive effects on knee OA pain, physical function,…
Abstract Number: 2155 • 2013 ACR/ARHP Annual Meeting
Beneficial Effect Of Long-Term Use Of a Low-Cost Minimalist Footwear On Joint Load, Clinical, and Functional Aspects Of Elderly Women With Knee Osteoarthritis
Francis Trombini-Souza¹, Alessandra Matias¹, Mariane Yokota¹, Marco Butugan¹, Ivye Pereira¹, Claudia Goldenstein-Schainberg², Ricardo Fuller³ and Isabel C.N. Sacco¹, ¹Physical Therapy, Speech and Occupational Therapy, School of Medicine, University of São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Division of Rheumatology - Hospital das Clinicas - Medical School, University of Sao Paulo, São Paulo, Brazil
Background/Purpose: Positive outcomes of minimalist shoes on reduction of overload in patients with knee osteoarthritis (OA) have been highlighted. We have recently shown beneficial effects…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at abstracts@rheumatology.org.